Unicycive Therapeutics (NASDAQ:UNCY) Upgraded to “Strong-Buy” at HC Wainwright

Unicycive Therapeutics (NASDAQ:UNCY) was upgraded by research analysts at HC Wainwright to a “strong-buy” rating in a research note issued to investors on Tuesday, MarketBeat Ratings reports. The brokerage currently has a $9.00 target price on the stock. HC Wainwright also issued estimates for Unicycive Therapeutics’ Q4 2026 earnings at $0.47 EPS.

Separately, Guggenheim initiated coverage on shares of Unicycive Therapeutics in a research note on Monday, April 21st. They set a “buy” rating and a $6.00 price objective on the stock.

Unicycive Therapeutics Stock Up 6.9%

UNCY opened at $0.59 on Tuesday. Unicycive Therapeutics has a 52-week low of $0.20 and a 52-week high of $0.96. The stock has a market cap of $71.30 million, a P/E ratio of -0.61 and a beta of 2.14. The business has a fifty day moving average of $0.59 and a 200 day moving average of $0.61.

Unicycive Therapeutics (NASDAQ:UNCY) last posted its quarterly earnings results on Wednesday, May 14th. The company reported ($0.05) earnings per share for the quarter, beating the consensus estimate of ($0.14) by $0.09. Equities analysts anticipate that Unicycive Therapeutics will post -0.23 EPS for the current fiscal year.

Institutional Investors Weigh In On Unicycive Therapeutics

A number of hedge funds have recently made changes to their positions in the stock. Northern Trust Corp grew its stake in Unicycive Therapeutics by 142.4% in the fourth quarter. Northern Trust Corp now owns 58,181 shares of the company’s stock valued at $46,000 after purchasing an additional 34,183 shares during the last quarter. XTX Topco Ltd boosted its stake in shares of Unicycive Therapeutics by 142.2% in the fourth quarter. XTX Topco Ltd now owns 171,463 shares of the company’s stock worth $136,000 after buying an additional 100,679 shares during the last quarter. Geode Capital Management LLC raised its position in Unicycive Therapeutics by 30.3% during the fourth quarter. Geode Capital Management LLC now owns 524,487 shares of the company’s stock valued at $417,000 after acquiring an additional 122,089 shares in the last quarter. Acuta Capital Partners LLC boosted its position in Unicycive Therapeutics by 16.4% in the 4th quarter. Acuta Capital Partners LLC now owns 2,303,000 shares of the company’s stock worth $1,829,000 after purchasing an additional 323,801 shares in the last quarter. Finally, Vivo Capital LLC increased its holdings in shares of Unicycive Therapeutics by 14.0% during the 1st quarter. Vivo Capital LLC now owns 11,370,152 shares of the company’s stock valued at $6,537,000 after purchasing an additional 1,400,000 shares in the last quarter. 40.42% of the stock is currently owned by hedge funds and other institutional investors.

Unicycive Therapeutics Company Profile

Unicycive Therapeutics, Inc, a biotechnology company, engages in developing novel therapies for kidney diseases in the United States. It is developing Renazorb for treatment of hyperphosphatemia in patients with chronic kidney disease on dialysis; and UNI 494, which is in Phase 1 clinical trials for treatment of acute kidney injury.